Menu
Recruiting NCT07420582

Antegrade Autologous Blood Reinfusion After CPB

— Observational Coronary Artery Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Antegrade Pump Blood Reinfusion, No Anterograde Pump Blood Reinfusion.
Who it may be relevant to
Registry conditions: Coronary Artery Disease. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Effect of Antegrade Pump Blood Reinfusion Via Crystalloid "Chase" Technique on Postoperative Transfusion Requirements in Adult Cardiac Surgery Patients: A Prospective Observational Study

Overview

This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.

Interventions

  • Procedure Antegrade Pump Blood Reinfusion
    Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom antegrade pump blood reinfusion is performed at the end of bypass using the crystalloid chase technique, as part of routine clinical practice.
  • Other No Anterograde Pump Blood Reinfusion
    Adult patients undergoing cardiac surgery with cardiopulmonary bypass in whom anterograde pump blood reinfusion is not performed at the end of bypass. Standard institutional clinical management is applied.

Primary outcome measures

  • Postoperative Blood Transfusion Requirement [Time frame: From the end of surgery to 24 hours postoperatively]
Secondary outcome measures (2)
  • Postoperative Drainage Volume [Time frame: From the end of surgery to 24 hours postoperatively]
  • Number of Transfused Blood Units [Time frame: From the end of surgery to 24 hours postoperatively]

Eligibility criteria

Inclusion criteria

  • Age 18 to 80 years
  • Patients undergoing elective, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass (on-pump).

Exclusion criteria

  • Emergency or Redo cardiac surgery
  • Concomitant cardiac procedures (e.g., valve repair/replacement or aortic surgery).
  • Planned or intraoperative conversion to off-pump coronary artery bypass grafting
  • Preoperative hematocrit <30% or known inherited/acquired bleeding disorders.
  • Preoperative left ventricular ejection fraction <30%.
  • Thrombocytopenia (e.g., platelet count <100×10³/µL) or abnormal coagulation tests.
  • Use of antiplatelet agents other than aspirin without appropriate discontinuation according to current guideline-recommended preoperative intervals.
  • Use of anticoagulant therapy without appropriate preoperative discontinuation according to current guideline recommendations.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) without appropriate discontinuation prior to surgery.
  • Severe renal dysfunction (eGFR <30 mL/min/1.73 m² or dialysis) and/or severe hepatic dysfunction (Child-Pugh B-C or coagulopathy).
  • Active infection or systemic inflammatory/autoimmune disease.
  • Active malignancy requiring ongoing treatment
  • Refusal or inability to provide written informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Kocaeli City Hospital — Kocaeli

Identifiers

NCT: NCT07420582 · KSH_ZYT_1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗